welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
FapulousTVhttps://www.youtube.com/channel/UCRuZby3...
-
Woman with Ostomy Bag Refused Entry to Bathroom with Disability AccessThat’s the message English blogger Sam...
-
Familial Adenomatous Polyposis (FAP): InheritedFAP is an inherited colorectal cancer sy...
-
Efficacy and Safety of Eflornithine (CPP-1X)/Sulindac Combination Therapy Versus Each as Monotherapy in Patients wit...BACKGROUND: Molecular studies suggest i...
-
Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer SyndromesThis is an observational, case-control s...
-
Strategy for Surgery in Familial Adenomatous Polyposis Patients with Invasive Colorectal CancerPURPOSE : Total proctocolectomy with ile...